NCT05156281: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05156281 |
|---|---|
| Title | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 13, 2021 |
| Completion date | April 30, 2026 |
| Required reporting date | April 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |